Australia markets open in 4 hours 44 minutes

BiomX Inc. (PHGE-UN)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
5.520.00 (0.00%)
As of 2:08PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.52
Open6.12
Bid4.98 x 1000
Ask6.06 x 2200
Day's range5.52 - 6.12
52-week range5.52 - 6.12
Volume1
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.42
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est23.00
  • GlobeNewswire

    BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study

    12-Week Study of BX001 Meets Safety and Tolerability Endpoints Statistically Significant Improvement from Baseline Observed in Appearance of Acne-prone Skin but No Meaningful Difference Demonstrated Relative to Vehicle Subject Satisfaction Questionnaire Outcomes Indicate Preference for BX001 Over Vehicle on Key Parameters BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 18, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advan

  • GlobeNewswire

    BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

    BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today that it has entered into an agreement granting Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, a right of first offer to license BiomX’s atopic dermatitis product candidate, BX005, in

  • GlobeNewswire

    BiomX to Present at Upcoming September Investor Conferences

    BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced Jonathan Solomon, Chief Executive Officer, will be presenting at three upcoming virtual investor events in September. Presentation Details: Event: H.C. Wainwright 23rd Annual Global Investments ConferenceDate: Monda